The Use Of Metformin In Preventing Obesity And Metabolic Syndrome In Early Psychosis

Presentation First Author: 
Philip B Ward

The relationship between weight gain and the treatment of first episode psychosis (FEP) with psychotropic medication has been well established, with obesity and metabolic syndrome common sequelae. Such metabolic abnormalities create further disease burden on a population already dealing with mental illness, whose life expectancy is approximately 20 years less than the general population, primarily due to cardiovascular complications. Antipsychotic-induced weight gain has been shown to commence within the first months of initiating treatment in drug naïve youth, thus early intervention is necessary in order to prevent or slow the progression of metabolic abnormalities. Initial studies using metformin in this population have shown promising results in terms of reversing or slowing weight gain and metabolic syndrome. This study aims to examine the preventative efficacy of initiating metformin in drug naïve FEP youth who are enrolled in the Early Psychosis Program (EPP) in Sydney, Australia, at the commencement of their antipsychotic treatment. Data from a historical cohort, not prescribed metformin, will be used as a comparison.

Conference Name: 
Presentation Date: 
January, 2013
Additional Authors: 
Philip B Ward, Stephanie Roland, Li Xian Lim, Jackie Curtis, Katherine Samaras
See other presentations in this session: